

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Gelofusine 40mg/ml Solution for Infusion

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

per 500 ml per 1000 ml

Succinylated Gelatin (= modified fluid gelatin) 20.0g 40.0g

(Molecular weight, weight average: 26,500 Daltons)

Sodium Chloride 3.51g 7.01g

Sodium Hydroxide 0.68g 1.36g

Electrolytes

Na<sup>+</sup> 77.0mmol 154.0mmol

Cl<sup>-</sup> 60.0mmol 120.0mmol

For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Solution for infusion.

A clear, colourless or slightly yellowish aqueous solution.

*Physico-Chemical Properties:*

pH 7.4 ± 0.3

Relative viscosity (at 37°C) 1.9

Iso-electric point pH 4.5 ± 0.3

Colloid osmotic pressure (at 37°C) 453 mm H<sub>2</sub>O

33.3 mm Hg

Gel point <math>\leq + 3^{\circ}\text{C}</math>

Osmolarity 274 mOsm/l

## 4 CLINICAL PARTICULARS

### 4.1 Therapeutic Indications

Gelofusine is a colloidal plasma volume substitute for:

- Treatment of relative or absolute hypovolaemia and shock
- Prophylaxis of hypotension

- caused by relative hypovolaemia during induction of epidural or spinal anaesthesia

- due to imminent significant blood loss in a surgical setting;

- Procedures involving extracorporeal circulation as a component of priming fluid in combination with crystalloid solutions (e.g. heart-lung machine).

### 4.2 Posology and method of administration

As with all colloids, Gelofusine should only be used if hypovolaemia cannot be sufficiently treated with crystalloids alone. In severe hypovolaemia colloids are usually applied in combination with crystalloids.

Volume overload due to overdose or too rapid infusion must always be avoided. The dosage must be adjusted carefully, particularly in patients with pulmonary or cardiocirculatory problems.

### **Posology**

Dosage and infusion rate are adjusted according to the amount of blood loss and to individual needs for restoration and maintenance of a stable haemodynamic situation, respectively. The dose administered is initially 500 to 1000 ml on average, in case of severe blood loss higher doses can be applied.

#### *Adults*

In adults, 500 ml is administered at an appropriate rate depending on the haemodynamic status of the patient. In the case of more than 20 per cent blood loss usually blood or blood components should be given in addition to Gelofusine (see 4.4).

#### *Maximum dose*

The maximum daily dose is determined by the degree of haemodilution. Care must be taken to avoid a decrease of the haemoglobin or haematocrit below critical values.

If necessary, blood or packed red cells must be transfused additionally.

Attention must also be paid to the dilution of plasma proteins (e.g. albumin and coagulation factors), which must be adequately substituted if necessary.

#### *Infusion rate*

Up to the first 20 ml of solution should be infused slowly in order to detect anaphylactic/anaphylactoid reactions as early as possible (see also section 4.4).

In severe, acute situations, Gelofusine may be infused rapidly by pressure infusion, 500 ml can be administered in 5 – 10 minutes, until signs of hypovolaemia are relieved.

#### *Paediatric population*

The safety and efficacy of Gelofusine in children have not yet been completely established. Therefore, no recommendation on a posology can be made. Gelofusine should only be administered to these patients if the expected benefits clearly outweigh potential risks. In those cases the patient's prevailing clinical condition should be taken into account and the therapy should be monitored especially carefully. (See also section 4.4.)

#### *Elderly patients*

Caution should be exercised in patients suffering from further diseases like cardiac insufficiency or renal insufficiency that are frequently associated with advanced age (see also section 4.4).

### Method of administration

Intravenous use.

Before rapid infusion, Gelofusine may be warmed to not more than 37°C.

In case of pressure infusion which might be necessary in vital emergencies, all air must be removed from container and the infusion set before the solution is administered. This is to avoid the risk of air embolism that might otherwise be associated with the infusion.

## **4.3 Contraindications**

- Hypersensitivity to gelatin- containing solutions or to any of the excipients listed in section 6.1
- Hypersensitivity to galactose- $\alpha$ -1,3-galactose (alpha-Gal) or known allergy to red meat (mammal meat) and offal (see section 4.4)
- Hypervolaemia
- Hyperhydration
- Acute congestive cardiac failure

## **4.4 Special warnings and precautions for use**

### *Anaphylactic/ anaphylactoid reactions*

Modified fluid gelatin solutions should be administered with caution to patients with a history of allergic diseases, e.g. asthma.

Modified fluid gelatin solutions may rarely cause allergic (anaphylactic/anaphylactoid) reactions of varying degrees of severity. In order to detect the occurrence of an allergic reaction as early as possible, the first 20 ml should be infused slowly and the

patient should be under careful observation especially at the beginning of the infusion. For symptoms of anaphylactoid reactions, see section 4.8.

Due to possible cross-reactions involving the allergen galactose-alpha-1,3-galactose (alpha-Gal), the risk of sensitization and consequent anaphylactic reaction to gelatin-containing solutions could be highly increased in patients with history of allergy to red meat (mammal meat) and offal and/or tested positive for anti-alpha-Gal IgE antibodies. Gelatin-containing colloidal solutions should not be used in these patients (see section 4.3).

In case of an allergic reaction, the infusion must be stopped immediately and appropriate treatment given.

#### *Risks related to fluid and electrolyte administration*

Gelofusine should only be administered with caution to patients

- at risk due to circulatory overload e.g. patients with right or left ventricular insufficiency, hypertension, pulmonary oedema or renal insufficiency with oligo- or anuria.
- with severely impaired renal function
- with severe hyponatraemia
- with severe hypernatraemia
- with severe hyperchloraemia
- having oedema with water/salt retention
- with major blood coagulation disorders
- of advanced age (elderly patients) as those are more prone to develop disorders such as cardiac or renal insufficiency

Clinical monitoring should include regular checks of serum electrolyte concentrations, acid-base balance and water balance, in particular in patients with hypernatraemia, hyperchloraemia or impairment of renal function. Gelofusine contains supraphysiological concentrations of sodium (154 mmol/L) and chloride (120 mmol/L).

Special attention should be paid to the appearance of symptoms of hypocalcaemia (e.g. signs of tetany, paraesthesia); then specific corrective measures should be taken.

#### *Influence on haemodilution and blood coagulation*

The haemodynamic, haematological and coagulation system should be monitored.

During compensation of severe blood losses by infusions of large amounts of Gelofusine, haematocrit and electrolytes must be monitored. The haematocrit should not decrease below 25%. In elderly or critically ill patients it should not fall below 30%.

Likewise in those situations the dilution effect on coagulation factors should be observed, especially in patients with existing disorders of haemostasis.

Because the product does not substitute lost plasma protein, it is advisable to check the plasma protein concentrations, see also section 4.2, "Maximum dose".

#### *Paediatric population*

There is insufficient experience with the use of Gelofusine in children. Therefore, Gelofusine should only be administered to these patients if the expected benefits clearly outweigh potential risks. (See also section 4.2).

#### *Influence on laboratory tests*

Laboratory blood tests (blood group or irregular antibodies) are possible after Gelofusine infusions. Nevertheless it is recommended to draw blood samples before the infusion of Gelofusine in order to avoid hampered interpretation of results.

Gelofusine may have an influence on the following clinical-chemical tests, leading to falsely high values:

- erythrocyte sedimentation rate,
- specific gravity of urine,
- unspecific protein assays, e.g. the biuret method.

### **4.5 Interaction with other medicinal products and other forms of interactions**

Caution should be exercised in patients concurrently taking or receiving medicinal products that can cause sodium retention (e.g. corticosteroids, non-steroidal anti-inflammatory agents) as concomitant administration may lead to oedema.

#### 4.6 Fertility, pregnancy and lactation

##### *Pregnancy*

There are no or limited amount of data from the use of Gelofusine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).

Due to the limited data available and the possibility of severe anaphylactic/anaphylactoid reactions, with consecutive foetal and neonatal distress due to maternal hypotension, the use of modified fluid gelatin solutions during pregnancy should be restricted to emergency situations.

##### *Breast-feeding*

There are no or limited data regarding the excretion of succinylated gelatine in mother's milk, but because of its high molecular weight it is not expected that the milk will contain relevant amounts. Sodium and chloride are normal constituents of the human body and of food. No significant increase in the content of these electrolytes in mother's milk is expected following the use of Gelofusine.

##### *Fertility*

There are no data on the effect of Gelofusine on human or animal fertility. However, because of the nature of its constituents it is considered unlikely that Gelofusine will affect fertility.

#### 4.7 Effects on ability to drive and use machines

Gelofusine has no or negligible influence on the ability to drive and use machines.

#### 4.8 Undesirable effects

Undesirable effects are listed according to their frequencies as follows:

Very common: ( $\geq 1/10$ )

Common: ( $\geq 1/100$  to  $< 1/10$ )

Uncommon: ( $\geq 1/1,000$  to  $< 1/100$ )

Rare: ( $\geq 1/10,000$  to  $< 1/1,000$ )

Very rare: ( $< 1/10,000$ )

Not known: (cannot be estimated from the available data)

##### Summary of the safety profile

Adverse drug reactions can occur during and after the use of Gelofusine. These will usually involve anaphylactoid/anaphylactic reactions of varying severity (see also sections 4.3 and 4.4, notably for hypersensitivity to galactose- $\alpha$ -1,3-galactose (alpha-Gal) and allergy to red meat and offal).

##### Tabulated list of adverse reactions

###### *Immune system disorders*

Rare: Anaphylactic/anaphylactoid reactions up to shock (see section 4.4)

###### *Cardiac disorders*

Very rare: Tachycardia

###### *Vascular disorders*

Very rare: Hypotension

###### *General disorders and administration site conditions*

Very rare: Fever, chills

###### *Gastro intestinal disorders*

Unknown: Nausea, vomiting, abdominal pain

###### *Investigations*

Unknown: Oxygen saturation decreased

### *Blood and lymphatic system disorders*

Very common: Decreased haematocrit and reduced concentration of plasma proteins

Common (depending on the administered dose):

Relatively large doses of Gelofusine result in dilution of coagulation factors and can therefore affect blood coagulation.

Prothrombin time can be increased and activated partial thromboplastin time (aPTT) can be prolonged after administration of large doses of Gelofusine (see section 4.4).

### Information on particular undesirable effects

*Mild anaphylactoid reactions include:*

Generalised erythema, urticaria, periorbital oedema, or angiooedema.

*Moderate anaphylactoid reactions include:*

Dyspnoea, stridor, wheeze, nausea, vomiting, dizziness (presyncope), diaphoresis, chest or throat tightness, or abdominal pain.

*Severe anaphylactoid reactions include:*

Cyanosis or  $\text{SaO}_2 \leq 92\%$  at any stage, hypotension (systolic blood pressure  $< 90$  mmHg in adults), confusion, collapse, loss of consciousness, or incontinence.

In the event of an anaphylactoid reaction, the infusion must be discontinued immediately and the usual acute treatment given.

### Paediatric population

There are no data relating to a special pattern or incidence of adverse reactions in paediatric patients.

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRC Pharmacovigilance, Website: [www.hpra.ie](http://www.hpra.ie)

## **4.9 Overdose**

### *Symptoms*

Overdose of Gelofusine may cause hypervolaemia and circulatory overload, with a significant fall in haematocrit and plasma proteins, accompanied by an electrolyte and acid base imbalance. This may be associated with consecutive impairment of heart and lung function (pulmonary oedema). Symptoms of circulatory overload are e.g. headache, dyspnoea, and jugular vein congestion.

### *Treatment*

In case circulatory overload appears, the infusion must be stopped and a rapid-acting diuretic should be given. If an overdose occurs, the patient should be treated symptomatically with monitoring of electrolytes.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmaco-therapeutic group:

Blood substitutes and plasma protein fractions

ATC code: B05A A06, gelatin agents.

### Mechanism of action

Gelofusine is a 40 mg/ml solution of succinylated gelatin (also known as modified fluid gelatin) with an average molecular weight of 26,500 Dalton (weight average).

The negative charges introduced into the molecule by succinylation causes an expansion of the molecule. The molecular volume is therefore higher than that of unsuccinylated gelatin of the same molecular weight.

In healthy volunteers, the measured initial volume effect of Gelofusine was found to be between 80 and 100 % of the infused volume with a volume effect over 4-5 hours.

The colloid-osmotic pressure of the solution determines the extent of its initial volume effect. The duration of the effect depends on the clearance of the colloid mainly by excretion. Since the volume effect of Gelofusine is equivalent to the administered amount of solution. Gelofusine is a plasma substitute, not a plasma expander. The solution also restores the extravascular compartment and does not disturb the electrolyte balance of the extracellular space.

#### Pharmacodynamic effects:

Gelofusine substitutes intra- and extravascular volume deficits caused by losses of blood or plasma and interstitial fluid. Thus the mean arterial pressure, the left-ventricular end-diastolic pressure, the cardiac stroke volume, the cardiac index, the oxygen supply, the microcirculation and the diuresis are increased without dehydrating the extravascular space.

#### Paediatric population

Only few clinical studies are available in the paediatric population. In 222 children with dengue shock syndrome aged 1-15 years, Gelofusine, dextran 70, Ringer's lactate, and isotonic saline performed equally well with regard to initial pulse pressure recovery time, subsequent episodes of shock, and development of any complication. **Out of 56 children who received Gelofusine, 5 (9%)** had an allergic reaction but recovered without sequelae. **(Ngo et al 2001)**.

In 14 children (**mean age 10 months**) undergoing surgery who received 15 ml/kg b.w. of Gelofusine during the first hour of surgery to maintain normovolaemia **(Haas et al, 2007)**, and in 25 children aged 0-12 years receiving Gelofusine for volume replacement after surgery (10 ml/kg b.w.) median coagulation values remained within the normal range **(Osthaus et al, 2009)**. No adverse events occurred in these studies.

In 776 preterm infants administered fresh frozen plasma, Gelofusine, or glucose at a dose of 20 ml/kg b.w. after birth and further 10 ml/kg b.w. after 24 h, no evidence was seen for any adverse short-term outcome related to gelatine use. The developmental outcome after two years was similar in the three groups **(Northern Neonatal Nursing Initiative Trial Group 1996a, 1996b, and Bailey et al 2010)**.

In 100 cyanotic paediatric patients (age 6 months to 3 years) undergoing cardiac surgery with cardiopulmonary bypass, Gelofusine 10-20 ml/kg (**n = 50**) in the priming solution was safe and effective. No adverse events were reported **(Miao et al 2014)**.

Overall, the data available for Gelofusine are too limited to fully assess the efficacy and safety in the paediatric population. (see section 4.2 and 4.4).

## **5.2 Pharmacokinetic properties**

#### Distribution:

After infusion, Gelofusine is rapidly distributed in the intravascular compartment.

#### Biotransformation/elimination:

The elimination of the modified gelatine takes place in 2 phases, with a half-life of approximately 8 hours for the first phase and a half-life of several days for the second phase. Most of the infused Gelofusine is excreted via the kidneys. Only a minor amount is excreted in faeces and not more than about 1 % is metabolised. The smaller molecules are excreted directly by glomerular filtration while the larger molecules are first degraded proteolytically in the liver and secondly are also excreted via kidneys.

#### Pharmacokinetics in special clinical situations:

The plasma half-life time of Gelofusine may be prolonged in patients on haemodialysis (GFR < 0.5 ml/min), however no accumulation of gelatine is observed.

## **5.3 Preclinical safety data**

No additional concerns identified.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Water for injections.

## **6.2 Incompatibilities**

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

## **6.3 Shelf life**

Shelf life of the medicinal product as packaged for sale:  
2 years.

Shelf life after first opening the container:  
The product should be used immediately after opening.

## **6.4 Special precautions for storage**

Do not store above 25°C.  
Do not refrigerate or freeze.

## **6.5 Nature and contents of container**

Gelofusine is available in the following containers and pack sizes:

1 x 20 Polypropylene Bags (Ecobag) of 500 ml  
1 x 10 Polypropylene Bags (Ecobag) of 1000 ml

Not all pack sizes may be marketed

## **6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product**

No special requirements for disposal.

The product is supplied in containers for single-use, only. Unused contents of an opened container must be discarded and not be stored for later use. Do not reconnect partially used containers.

Only to be used if solution is clear, colourless or slightly yellowish and the container and its closure are undamaged.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7 MARKETING AUTHORISATION HOLDER**

B. Braun Melsungen AG  
Carl-Braun-Straße 1  
34212 Melsungen  
Germany

## **8 MARKETING AUTHORISATION NUMBER**

PA0736/011/001

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 03 March 2000  
Date of last renewal: 03 March 2010

## **10 DATE OF REVISION OF THE TEXT**

February 2022

**References**

- Bailey et al 2010 Bailey AG, McNaull PP, Jooste E, Tuchman JB. Perioperative crystalloid and colloid fluid management in children: where are we and how did we get here? *Anesth Analg* 2010 Feb 1;110(2):375-90.
- Haas et al 2007 Haas T, Preinreich A, Oswald E, Pajk W, Berger J, Kuehbacher G, Innerhofer P. Effects of albumin 5% and artificial colloids on clot formation in small infants. *Anaesthesia* 2007 Oct;62(10):1000-7.
- Miao et al 2014 Miao X, Liu J, Zhao M, Cui Y, Feng Z, Zhao J, Long C, Li S, Yan F, Wang X, Hu S. The influence of cardiopulmonary bypass priming without FFP on postoperative coagulation and recovery in pediatric patients with cyanotic congenital heart disease. *Eur J Pediatr*. 2014 Nov;173(11):1437-43.
- Ngo et al 2001 Ngo NT, Cao XT, Kneen R, Wills B, Nguyen VM, Nguyen TQ et al. Acute management of dengue shock syndrome: a randomized double blind comparison of 4 intravenous fluid regimens in the first hour. *Clin Infect Dis* 2001 Jan 15;32(2):204-13.
- Northern Neonatal Nursing Initiative Trial Group 1996a Northern Neonatal Nursing Initiative Trial Group. A randomized trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin or glucose on early mortality and morbidity in preterm babies. *Eur J Pediatr* 1996a Jul;155(7):580-8.
- Northern Neonatal Nursing Initiative Trial Group 1996b Northern Neonatal Nursing Initiative Trial Group. Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years. *The Lancet* 1996b Jul 27; 348(9022):229- 32
- Osthaus et al 2009 Osthaus WA, Witt L, Johanning K, Boethig D, Winterhalter M, Huber D, Heimbucher C, Suempelmann R. Equal effects of gelatin and hydroxyethyl starch (6% HES 130/0.42) on modified thrombelastography in children. *Acta Anaesthesiol Scand* 2009 Mar;53(3):305-10.